Preliminary amendment (Amendment C) and response to Office Action dated December 7, 2006 March 7, 2007

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

- 1. (Currently amended) A transdermal delivery system (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine, and a protective foil or sheet to be removed prior to use, eharacterized in that wherein the self-adhesive matrix consists of comprises a solid or semi-solid semi-permeable polymer
 - (1) wherein rotigotine in its free base form has been is incorporated,
 - (2) which is saturated with rotigotine and contains said rotigotine as comprises a multitude of microreservoirs within the matrix, said microreservoirs containing rotigotine and optionally at least a crystallization inhibitor,
 - (3) which is **highly** permeable [[for]] to the free base of rotigotine,
 - (4) which is <u>substantially</u> impermeable [[for]] <u>to</u> the protonated form of rotigotine, <u>and</u>
 - (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix;

and wherein the backing layer is inert to the components of the matrix.

- 2. (Currently amended) The TDS according to of claim 1, characterized in that wherein the mean diameter of the microreservoirs is in the range of 0.5 to 20 μm.
- 3. (Currently amended) The TDS according to of claim 1, characterized in wherein the self-adhesive matrix [[being]] is free of particles that can absorb salts of rotigotine at the TDA/skin TDS/skin interface.
- 4. (Currently amended) The TDS according to of claim 1, characterized in that wherein the polymer matrix comprises a silicone[[-type]] pressure sensitive adhesive.
- 5. (Currently amended) The TDS according to of claim 1, characterized in that wherein the polymer matrix comprises two or more silicone[[-type]] pressure sensitive adhesives as the main adhesive components.

- 6. (Currently amended) The TDS according to of claim 5, wherein the two or more silicone [[type]] pressure sensitive adhesive is adhesives comprise a blend of a high tack silicone [[type]] pressure sensitive adhesive comprising polysiloxane with a resin and a medium tack silicone [[type]] pressure sensitive adhesive adhesive comprising polysiloxane with a resin.
- 7. (Currently amended) Method A method for treatment of a patient suffering from a disease treatable [[by]] with rotigotine, comprising [[by]] applying the TDS according to of claim 1 to the skin of the patient.